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INTRODUCTION 
Nutritional deficiency disorders constitute a major health problem in 
India. In addition to direct implications for morbidity and mortality, 
undernutrition predisposes children and adults to various infections. Three 
micronutrients – vitamin A, iron and iodine are among the most important of 
all the nutrients needed by the body because they are vital for developing 
normal learning and cognitive functions, immune defence mechanism, work 
capacity and reproductive health1. Deficiency of these three micronutrients is 
known to have devastating effects on health. 
Anemia resulting from lack of sufficient iron for the synthesis of 
hemoglobin is the most common hematological disease of infancy and 
childhood21. It is estimated that 30% of the global population suffers from 
iron deficiency anemia; most of those affected live in developing countries21. 
Iron deficiency anemia occurs when iron absorption cannot 
compensate iron requirements and losses. Requirements are especially high 
in pregnant women, infants, young children and adolescents. The 
consequences of iron deficiency anemia are many and serious, affecting not 
only individual health but also the development of societies and countries.46  
In India, the prevalence of anaemia among adolescent girls is high. 
Adolescent girls are particularly vulnerable group as their requirements of 
iron as well as its losses from the body are high. And the bioavailability of 
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iron is also low in predominantly cereal based diets because of their high 
phytate content. Anemia is likely to compromise physical work capacity and 
cognitive functions of girls in the pubertal phase of development43. Anemia 
during adolescence limits growth and delays the onset of menarche, which 
inturn may later lead to cephalopelvic disproportion.  It results in increased 
maternal mortality and decreased child survival, as supplementation during 
pregnancy fails to restore the iron status.   
 Very often, in India, girls get married and become pregnant even 
before the growth period is over, making anemia doubly risky. Few 
programmes for anemia control have targeted adolescent girls and health 
care of adolescent girls all over the world has not been given priority.   
 Global Scenario 4-7 
Iron deficiency anemia affects nearly 2 billion people around the 
world. Of these nearly 90% are in the developing countries.  
Indian Scenario 4-7 
In India according to NSHF survey, 74% of children, 32 – 55% of 
adolescent girls and 50 – 60% of pregnant women are affected by iron 
deficiency anemia. 5.8 – 48.7% of pregnant women are severely anemic. 
19% of maternal death is attributed to iron deficiency anemia alone. 
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Tamil Nadu Scenario 4-7 
 In Tamil Nadu 69% of children and 44.8% of adolescent girls are 
affected by iron deficiency anemia. Though it is less than national level, it is 
more than the desired level. 
Anemia21 
Anemia is defined as a reduction of the red blood cell (RBC) volume 
or hemoglobin concentration below the range of values occurring in healthy 
persons.  Although a reduction in the amount of circulating hemoglobin 
decreases the oxygen-carrying capacity of the blood, few clinical 
disturbances occur until the hemoglobin level falls below 7–8 g/dl. Below 
this level, pallor becomes evident in the mucous membranes. When 
moderately severe anemia develops slowly, surprisingly few symptoms or 
objective findings may be evident. Weakness, tachypnea, shortness of breath 
on exertion, tachycardia, cardiac dilatation, and congestive heart failure 
ultimately result from increasingly severe anemia, regardless of its cause. 
Anemia is not a specific entity but, rather, the result of many underlying 
pathologic processes.       
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           Anemia with adequate response (Reticulocyte Production Index >3) 
1) Hemoglobinopathy Hemoglobin SS,S-C, Sβ thalassemia 
2) Enzymopathy G6PD def, pyruvate kinase def. 
3) Membranopathy Hereditary spherocytosis, elliptocytosis, 
ovalocytosis 
4) Extrinsic factors DIC, HUS, TTP, Burns, Vitamin E def., 
Abetalipoprotenemia, Wilson disease  
5) Immune hemolytic anemia Autoimmune, isoimmune, drug induced 
 
        Anemia with inadequate response (Reticulocyte Production Index<2)              
Microcytic hypochromic Normocytic normochromic  Macrocytic 
1)Iron deficiency   
2)Thalassemia  
3)Chronic inflammatory 
disease  
4)Copper deficiency  
5)Sideroblastic anemia  
6)Aluminium , lead 
intoxication  
7)Hereditary 
pyropoikilocytoses  
8)Hemoglobin CC,EE 
1)Chronic inflammatory dis.   
2)Recent blood loss  
3)Malignancy/marrow      
infiltration  
4)Chronic renal failure    
5)Transient erythro-
blastopenia of childhood  
6)Marrow aplasia/hypoplasia  
7)HIV infection  
8)Hemophagocytic syndrome   
1)Vitamin B12 def.  
2)Folate def.  
3)Hypothyroidism  
4)Marrow failure  
5)Orotic aciduria  
6)Chronic liver 
disease  
7) Lesch Nyhan 
syndrome  
8) Downs syndrome 
9) Drugs  
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A brief overview of the iron metabolism and iron deficiency anemia will 
help in understanding alternate strategies.   
Iron Metabolism and iron deficiency Anemia17, 21                                                              
Iron deficiency anemia is the most common anemia in the world. The 
fourth most abundant element in the earth’s crust, iron is only trace element 
in biologic systems, making up only 0.004% of the body’s mass. Yet it is an 
essential component or cofactor of numerous metabolic reactions. By 
weight, the great proportion of the body’s iron is dedicated to its essential 
role as a structural component of hemoglobin. Without sufficient iron 
available to the RBC precursors, normal erythropoiesis cannot take place, 
and anemia develops. On the other hand, iron is a toxic substance. Too much 
iron accumulating in vital structures (especially the heart, pancreas, and 
liver) produces a potentially fatal condition, hemochromatosis. Iron is an 
essential component of the hemoglobin molecule, without iron the marrow is 
unable to produce hemoglobin. The red cell number falls and those which do 
reach the circulation are smaller than normal (microcytic) and lack 
hemoglobin, hence they are pale and under coloured (hypochromic). The 
deficiency in iron may be absolute, that is, there is no iron available for the 
production of hemoglobin, and this is true iron deficiency anemia. The 
deficiency may be relative, that is, the iron is present in storage form in the 
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marrow but is unavailable for hemoglobin production, and this is anemia of 
chronic disease.     
Iron distribution 
The majority of the iron is present as hemoglobin iron. Approximately 
25% of the iron is maintained as storage iron (ferritin and hemosiderin) 
primarily in the bone marrow.  
        -Hemoglobin                                                  -1.5 to 3.0gm (65 to 70%)  
        -Storage               
                  Ferritin & Hemosiderin                         -0.5 to 1.5gm (20 to 30%)  
       -Others  
                  Myoglobin  
                  Heme enzyme remainder  
Iron absorption48 
Iron absorption occurs primarily in the duodenum. Most of the iron is 
in the ferric (+++) form and is complexed to other organic and inorganic 
molecules. The acid in the stomach and hydrolytic enzymes in the small 
intestine release the iron from these complexes. It is then reduced to the 
ferrous (++) form as it is more readily absorbed in this state. Absorption is 
increased by the presence of glucose, some amino acids, ascorbic acid 
(Vitamin C).  
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These substances aid in the absorption process by either reducing 
ferric iron to the ferrous state or by helping bind the iron to the mucosal cell 
receptor sites. Heme iron, iron in meat myoglobin, is more easily absorbed 
than elemental iron. Iron absorption is decreased by the presence of 
phosphate, bicarbonate, bile acids, phytates. 
Fe3+ reductase activity is associated with the iron transporter in the 
brush borders of the enterocytes . Once the ferrous iron (++) binds to 
receptors on the surface of mucosal cells it is moved into the cell via DMT1. 
Some is stored in ferritin, and the remainder is transported out of enterocytes 
by a basolateral transporter named ferroportin 1. A protein called hephaestin 
(Hp) is associated with ferroportin 1. It is not a transporter itself, but it 
facilitates basolateral transport. In the plasma, Fe2+ is converted to Fe3+ and 
bound to the iron transport protein transferrin. This protein has two iron-
binding sites. Bound to transferrin the iron is transported to the marrow for 
use or storage. Normally, transferrin is about 35% saturated with iron, and 
the normal plasma iron level is about 130mcg/dl in men and 110mcg/dl in 
women.     
Heme binds to apical transport protein in enterocytes and is carried 
into the cytoplasm. In the cytoplasm, HO2, a subtype of heme oxygenase, 
removes Fe2+ from porphyrin and adds it to the intracellular Fe2+ pool. 
Apoferritin is a globular protein made up of 24 subunits. Iron forms a 
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micelle of ferric hydroxyphospate, and in ferritin, the subunits surround this 
micelle. Ferritin is readily visible under electron microscope and has been 
used as a tracer in studies of phagocytosis and related phenomena. Ferritin 
molecules in lysosomal membranes may aggregate in deposits that contain as 
much as 50% iron. These deposits are called hemosiderin.   
Role of VitaminC in iron and folic acid absorbtion49  
Vitamin C helps in the intestinal absorption of iron. It does this by 
keeping the iron in a form that is more easily absorbed. Further, after the iron 
is absorbed, Vitamin C apparently aids in the transfer of iron from a protein 
that transports it in the body to a protein that stores it until it is needed. 
Certain enzymes (specialized proteins that keep the body’s metabolic 
machinery running) require iron to function properly. Several of these iron-
containing enzymes will not work unless Vitamin C is present. Folic acid 
deficiency can result in anemia. Vitamin C has been reported as necessary in 
the conversion of folic acid to the form of this vitamin that is active in the 
body. 
Regulation of iron absorption   
The intestinal walls covered with villi, finger-like projections, which 
are covered with absorptive mucosal cells. These cells are produced in the 
crypts of Lieberkuhn, at the base of the villi, and move upwards to the villus 
tip to be desquamated (lost). Each cell is produced with a set amount of 
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apoferritin. The more iron required by the body the less apoferritin 
manufactured in each cell. In other words, it is the amount of apoferritin 
within each mucosal cell which acts as the gatekeeper and regulates the 
amount of iron absorbed.   
Intestinal absorption of iron is regulated by three factors: recent 
dietary intake of iron, the state of the iron stores in the body, the state of the 
erythropoiesis in the bone marrow. However, the ways these factors signal 
the absorptive process still unsettled. 
Transferrin is the primary iron transport protein. It is a beta globulin 
and is produced in liver. It has a half- life of 8-11days. Each molecule of 
transferrin can bind and transport two molecules of iron in the ferric (+++) 
state. Transferrin prefers to carry iron to the marrow but will carry iron to the 
other organs if the marrow is damaged or excess amounts of iron are already 
stored in the marrow. In rare instances when transferrin is absent 
(atransferrinemia) other proteins can bind iron but carry the iron to the other 
organs such as liver, spleen and pancreas, little if any is carried to the 
marrow. As well as specific receptors for iron, transferrin has specific 
receptors for sites on the developing normoblast. Once bound to the cell 
membrane, the transferrin changes shape and releases the iron. It then returns 
to the portal circulation to bind more iron.   
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Iron transfer across the Red Cell membrane  
Iron can be transferred to developing red cells either bound to 
transferrin or presented as ferritin to the developing cells as they cluster 
around “nurse cell” RE cells. The iron is moved into the developing red cell. 
Clusters of normoblast around a nurse cell are called a “feed island”.   
Iron Storage 
Iron is stored as either ferritin or hemosiderin: ferritin consists of an 
outer protein shell with iron complexed within the core. The outer shell 
consists of 22 apoferritin molecules while the core consists of an 
iron/phosphate complex consisting of 4,000 to 5,000 molecules of iron in 
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each core. Ferritin is water soluble and a very small amount dissolved in 
plasma.   
The ferritin reference range for males is 15-200ng/ml, 12-150 ng/ml 
for females and for children 6 months to 15 years is 7-140ng/ml. Ferritin is 
not visible by light microscopy, nor is stained by the Prussian blue reaction. 
Hemosiderin is aggregated ferritin molecules. The protein shell has been 
altered and as a result it is water insoluble. It can be seen by light 
microscopy as gold brown granules and is demonstrated by the Prussian blue 
stain.  
Daily Iron Requirements     
The adult male requires approximately 1mg/day, just enough to cover 
normal iron loss. The adult female requires approximately 2mg/day, enough 
for daily loss and menstruation. Pregnant females require approximately 
3mg/day, enough for normal, ongoing loss and fetal requirements. Children 
require approximately 2mg/day, enough for normal loss and extra to produce 
some residual iron stores and allow for increasing red cell mass.  
Causes of Iron Deficiency   
• Diet –uncommon except in children  
• Failure to absorption iron  
• Increased utilization  
• Pregnancy  
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• Adolescent growth  
• Atransferrinemia   
• Failure to utilize  
• Lead poisoning   
• Chronic diseases  
• Blood loss  
          Chronic blood loss is an important cause of iron deficiency anemia 
particularly in older children17. 
Development of iron deficiency anemia  
It must be remembered that anemia in deficiency develops slowly. 
Only 50% of people with iron deficiency develop iron deficiency anemia 
since this is a late manifestation of chronic iron deficiency. The type and 
severity of the anemia varies with time.  
Development Stages  
1. Depletion of iron stores, decreased ferritin levels, no anemia. 
2. Increased transferrin levels, no anemia.  
3. Fall in serum iron, no anemia.  
4. Development of normocytic, normochromic anemia.  
5. Development of microcytic, hypochromic anemia.  
The clinical manifestation may vary with age, degree and rapidity of 
onset and other factors. Mild anemia is often asymptomatic. The main 
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symptoms are exercise dyspnoea, fatigue, palpitation, pica (consumption of 
substances such as ice, starch or clay, frequently found in iron deficiency 
anemia), syncope (particularly following exercise) and bounding pulse. 
Dizziness, headache, syncope, tinnitus or vertigo, irritability, difficulty in 
sleeping or concentrating is more frequent in severe chronic anemia. Plasma 
ferritin level was significantly lower in children with first febrile seizure 
suggesting a possible role for iron insufficiency in first febrile seizures.  
In the period of later school age and early adolescence, compromised 
pubertal growth spurt, reduced physical work capacity and cognitive 
function, poor scholastic performance and behavioral disturbances.  
Common signs are pallor (color of skin, oral and conjunctival mucous 
membrane and nail beds), tachycardia, ejection systolic murmur, mild 
peripheral edema and venous hum and wide pulse pressure. In old people, 
angina pectoris can be an important clinical manifestation.  
Cardiovascular Adaptations in Anemia:  
The main consequence of anemia is tissue hypoxia. If anemia has 
developed rapidly, there may not be adequate time for compensatory 
adjustments to take place, so there is sudden marked contraction of 
intravascular volume, resulting in postural hypotension, fall in cardiac 
output, shunting of blood from skin to central organs, sweating, restlessness, 
thirst and air hunger. If anemia occurs slowly, many adaptations occur for 
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the oxygen maintenance, such as increasing of plasma volume and right shift 
of the oxygen-hemoglobin dissociation curve. 
Laboratory Diagnosis of Iron Deficiency 
Routine procedures: 
Hb, Hct, and RBC count are all decreased. The degree of decrease 
depends upon the length of time the marrow has been without sufficient 
supplies of iron. It must be remembered that at any stage the red cell number 
will not be proportionately as low as is the Hb and Hct. This is due to the 
fact that the marrow can continue to produce cells which are deficient in 
hemoglobin.   
Methods used to estimate Hemoglobin are12:  
1. Direct cyanmethemoglobin method- drabkins solution added to the 
blood results read by spectrophotometry-Gold standard  
2. Indirect cyanmethemoglobin method- blood collected in whatman 
filter paper and dried after that drabkins solution added and the 
results analysed.  
3. Hemocue method-blood collected in microcuvette directly and 
analysed in spectrophotometer, used in field surveys and in remote 
areas. 
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Hematologic Values During Infancy and Childhood21 
 Hemoglobin(g/dl) Hematocrit(%) Reticulocytes(%) MCV(fl) 
AGE Mean Range Mean Range Mean Lowest 
Cord blood 16.8 13.7–20.1 55 45–65 5.0 110 
2 wk 16.5 13.0–20.0 50 42–66 1.0  
3 mo 12.0 9.5–14.5 36 31–41 1.0  
6 mo–6 yr 12.0 10.5–14.0 37 33–42 1.0 70–74 
7–12 yr 13.0 11.0–16.0 38 34–40 1.0 76–80 
Adult Female 14 12.0–16.0 42 37–47 1.6 80 
Adult Male 16 14.0–18.0 47 42–52  80 
 
Special procedures: 
A bone marrow examination is seldom, if ever, performed or needed 
for the diagnosis of an iron deficiency anemia. If however, a bone marrow is 
performed the following results would be present.  
Bone Marrow: 
Cellularity – normal to increased. 
Morphology - normoblastic with some dyserythropoiesis. Ragged 
reduced cytoplasm, vacuoles, multinuclearity, karyorrhexis, nuclear budding, 
abnormal mitosis. All these may be seen but are not the predominant features 
of the marrow. Iron stain - absent. The absence of iron is considered to be 
the “gold standard” for the diagnosis of iron deficiency.  
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The other findings are: 
Siderocytes –absent  
Serum iron –decreased  
TIBC – increased.  
% saturation – decreased.  
Ferritin – decreased.  
Free erythrocyte protoporphyrin (FEP) – increased. 
Treatment  
Iron supplementation is the main stay of treatment. A daily total dose 
of 4–6 mg/kg of elemental iron in 3 divided doses provides an optimal 
amount of iron for the stimulated bone marrow to use21.  The response is 
monitored with reticulocyte count, hemoglobin and hematocrit.  
 Responses to iron therapy in iron deficiency anemia.21 
Time after iron administration Response 
12-24 Hrs 
Replacement of intracellular iron enzyme 
subjective improvement, decreases 
irritability, increases appetite 
36-48 Hrs 
Initial bone marrow response: erythroid 
hyperplasia 
48-72 Hrs Reticulocytosis, peaking at 5-7days 
4-30 days Increase in hemoglobin levels 
1-3 Months Repletion of iron stores 
 Iron treatment should be continued for 8 weeks after blood values are 
normal to replace the stores.  
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Failure to respond may be due to:  
1. continued bleeding  
2. failure to take iron  
3. wrong diagnosis            
4. mixed deficiency  
5. other causes – inflammation  
6. malabsorption – unlikely    
  
VITAMIN C47 
Vitamin C (ascorbic acid) is water-soluble vitamin. It is the most sensitive of 
all vitamins to heat. Man, monkey and guinea pig are perhaps the only 
species that require vitamin C in their diet.  
Functions are: 
1. Potent antioxidant  
2. Needed for the formation of collagen and collagen provides a supporting 
matrix for the blood vessels and connective tissue, and for bones and 
cartilage.  
3. Facilitates absorption of iron from vegetables by reducing ferric iron to 
ferrous iron.  
4. It inhibits nitrosamine formation by intestinal mucosa. 
 
  24
Sources are: 
The main dietary sources are fresh fruits and green leafy vegetables. 
Traces of vitamin C occur in fresh meat and fish but scarcely in cereals. 
Germinating pulses contain good amounts. Roots and tubers contain small 
amounts. Amla or the Indian gooseberry is one of the richest sources of 
vitamin C both in fresh as well as in the dry condition. Guavas are another 
cheap but rich sources of vitamin C.  
Deficiency leads to: 
Scurvy, signs of which are swollen and bleeding gums, subcutaneous 
bruising or bleeding into the skin or joints, delayed wound healing, anemia 
and weakness.  
Requirement: 
The estimated requirement for vitamin C has been recently raised from 
40 to 60mg with much larger doses advocated by some.    
Strategies to prevent iron deficiency anemia 
The major factors responsible for iron deficiency anemia in 
developing countries are reduced intake and poor bioavailability of dietary 
iron. The iron requirements in different age groups are different. 
 WHO expert group proposed that anemia should be considered to 
exist when hemoglobin is below the following levels.42 
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Cut-Off points for the diagnosis of anemia: 
 gm/dl (Venous blood) 
Adult males 13 
Adult females, Non-pregnant 12 
Adult females, Pregnant 11 
Children, 6 Months to 6 Years 11 
Children, 6 Years to 14 Years 12 
  
Different interventions are needed for the prevention and the control 
of iron deficiency. Iron fortification of staple foods or condiments directed to 
the whole population is a sustainable and cost-effective approach. However, 
at some periods of life, especially during pregnancy and in children from the 
age of 6 months, iron requirements are high. For pregnant women, the 
current approach favours the daily iron-folate supplementation during 
pregnancy but the results in terms of public health are disappointing. 
 For infants and young children, iron fortification of complementary 
food is effective but it is economically inaccessible to populations with 
limited resources. When complementary foods are not available, the 
preventive iron supplementation from 6 to 18 months of age has to be 
advised. These interventions are more effective when they integrate other 
approaches like the improvement of the nutritional practice, infection control 
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and the promotion of breastfeeding and when coupled with programs aiming 
to control other micronutrient deficiencies. The success of most interventions 
requires the active participation of the individual.46 
Information and education of the populations, especially through 
social mobilization campaigns, are essential because iron deficiency induces 
few visible symptoms not easily recognizable by individuals. The 
implementation of national nutrition plans including the control of iron 
deficiency as one of the priorities and the participation of the public health 
and the education sectors, food industries, the community and the media 
should contribute to the success of the intervention and to the control of iron 
deficiency. 
 The government of India has initiated a number of national 
programmes in the country to improve the health and nutritional status of the 
population.   
 National Nutritional Anemia Prophylaxis Programme2  
           To control iron deficiency anemia the National Nutritional Anemia 
Prophylaxis Programme (NNAPP) was launched in 1970 with main 
intervention of distribution of iron and folic acid tablets to expectant mothers 
and children. 
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Antenatal mothers were given 60mg of iron and 500mcg of folic acid 
for 100days in pregnancy and children were given a tablet 20mg of 
elemental iron and 100mcg folic acid.  
It has been shown that NNAPP did not have the desired impact on 
anemia prevalence. A multicentric study by Indian Council of Medical 
Research revealed that 17% of pregnant women had hemoglobin levels less 
than 9 gm% before iron supplementation was started and compliance rate 
was unsatisfactory in a considerable proportion of cases. This has been 
attributed to non-delivery of the tablets to the women, poor quality of tablets 
and non-consumption of tablets due to lack of awareness about the 
importance of iron.  
Side effects of oral iron therapy are also mentioned as a reason for 
non-compliance, but these are probably more highlighted than real. It was 
also noted that as high as 38% of women who had consumed the tablets 
regularly for more than 90 days during the last trimester had hemoglobin 
levels less than 10 gm% and in 20% less than 9 gm%. It was felt that 60 mg 
elemental iron is inadequate. So it was suggested that prophylaxis 
programme should be converted into a control programme.   
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National Nutritional Anemia Control Programme   
National Nutritional Anemia Control Programme was launched in 1991. 
Its objectives are: 
1. To assess the baseline prevalence of nutritional anemia in antenatal 
mothers and young children through estimation of hemoglobin levels. 
(Now it has been decided that severe anemia should be identified 
clinically as hemoglobin estimation has limited utility and there is risk 
of spread of diseases). 
2. To put the mothers with more than 10gm% and children with more 
than 8gm% on the prophylaxis programme. 
3. To monitor continuously the quality, distribution and consumption of 
IFA tablets. 
4. To assess periodically the hemoglobin levels of the beneficiaries. 
5. To motivate the beneficiary mothers to consume the tablets through 
relevant nutritional education and pass on the information to their 
children. 
Presently 27 million adults and 30 million child beneficiaries are 
covered under this programme. Also it has been made an integral part of 
CSSM programme. And now it is covered under RCH programme.  
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Pregnant women: 
One adult tablet per day for 100 days, each tablet containing 100mg 
elemental iron and 500mcg of folate and these should be provided after first 
trimester of pregnancy.  
Lactating women and IUD acceptors: 
One adult tablet for 100 days. 
Preschool children (1-3years): 
One small(pediatric) tablet containing 20 mg of elemental iron and 
100mg of folic acid for 100 days every year.   
Constraints of the present strategy:   
The recommended National Nutritional Anemia Control Programme 
advocating daily hematinics supplementation to pregnant women is not 
showing the expected results.  
These programmes have been ineffective, partly because side effects 
limit compliance; operational failures are the rule (e.g. Inadequate supplies 
and poor packaging and presentation of supplements), and health workers 
and recipients lack appropriate information and motivation46. 
The major constraints are irregular availability of hematinics and lack 
of education and communication of the importance of hematinics 
supplementation during pregnancy leading to its poor compliance among 
subjects.   
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Alternate strategies   
  Strategies such as dietary diversification and food fortification have 
yield significant results in controlling iron deficiency anemia in developed 
countries. Reducing the prevalence of iron deficiency anemia in developing 
countries is still a matter of importance. Dietary and food based approaches 
pose considerable challenges before they can be implemented on a wide 
scale.   
As the programmes did not show effective results in countries such as 
India, the dosage of iron was increased. Gastrointestinal distress 
(constipation, nausea, and diarrhea) are often experienced when consuming 
iron supplements, especially on an empty stomach. Therefore chronic, daily 
use of iron supplements in excess should be avoided.  
There are number of reports associating elevated iron stores with 
cardiovascular disease and cancer. However, there are no studies that have 
associated specific chronic intake levels of dietary or supplemental iron with 
CVD and cancer. It is not possible to estimate how much iron must be 
consumed to result in a specific level of iron stores.  
The upper limit (45mg/day) is for the general healthy population. 
Individuals with hemochromatosis may not be protected by the upper limit. 
Relative to an adult, the normal value for hemoglobin is high in neonates, 
falling to lower-than-adult values by 3-6 months, and rising gradually 
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thereafter to the adult value by the early teenage years. The role of excess 
iron in causing intestinal oxidative stress has drawn attention to other 
approaches of iron supplementation.  
Prophylactic administration of iron along with antioxidants like 
vitamins E and C or foods rich in these vitamins is one such strategy. In 
order to improve the compliance, reduce the cost of the therapy and reduce 
the intestinal oxidative stress schedules administering hematinics less than 
once daily have been tried. Gopalan C3 and Viteri FE9 in their studies have 
indicated that with continuous daily administration, iron absorption could 
decrease due to “tiredness” of the intestinal mucosa.  
According to a study, absorption from a single dose of iron reduces 
from 30-40% on the first day to as low as 3-6% after a few days of 
continuous daily administration. Studies carried out on preschoolers support 
that iron supplementation once or twice a week, increase their hemoglobin 
status significantly. The potential benefits and shortcomings of these 
approaches are reviewed. 
In experimental animals, the absorption of supplemental iron is 
greatest when it is administered at times of intestinal mucosal renewal, so 
that each dose is received by new cell which is based on the mucosal block 
theory. Thus, inhibition of iron absorption is minimized because of the iron 
overload in intestinal cells, which occurs with daily iron supplementation.  
  32
Because weekly supplementation with iron is effective at improving 
iron status, this option should be thoroughly explored and evaluated in the 
context of programs for the prevention and treatment of iron deficiency 
anemia.  
Weekly supplementation programs may improve the logistical and 
economic constraints that currently limit the provision of supplements to the 
many target population groups for whom they are recommended, but usually 
fail to reach. Further work is required to clarify the purpose, delivery and 
outcomes of iron supplementation programmes.  
 
ADOLESCENT PROGRAMMES IN INDIA  
Adolescent girls were not covered under National Nutritional 
Anaemia Control Programme (NNACP) or any other programme. 
Interventions for anaemic adolescent girls should raise their iron stores and 
sustain their hemoglobin at normal levels. This will not only improve their 
physical and mental capacity, but also subsequently help in reducing the 
incidence of low birth weight of infants and maternal mortality rates. 
Recognising the enormous potential of the school system, a project was 
initiated with support from UNICEF to prevent and control anemia in 
adolescent girls, utilising the school system.  
 
  33
Adolescent Girls Scheme 
The Adolescent Girls Scheme (AGS) or “Kishori Shakti Yojana” is 
part of the Integrated Child Development Services Scheme (ICDS), devised 
during 1991-92, for adolescent girls in the age group of 11-18 years. 
The scheme fills the gap in services for adolescents including school 
dropouts, as government schemes previously covered children (0-6 years), 
mothers and school going children. 
The main objectives of the scheme are: 
¾ To improve the nutrition and health status of girls in the age group of 
11-18 years; 
¾ To provide literacy and numeracy skills through non-formal 
education; 
¾ To train and equip adolescent girls to improve or upgrade home-based 
skills and to enable them to run child care centres at a later stage; 
¾ To promote awareness of health, hygiene, nutrition and family welfare 
issues and to encourage girls to marry after 18 years. 
The scheme provides ‘hands-on’ learning at the Anganwadi centre, 
education, health check-ups and supplementary nutrition. A major thrust of 
the programme is to prevent teenage pregnancies. 
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UNICEF adolescent anemia project  
UNICEF has initiated a project in 11 Indian states to provide iron and 
folic acid tablets to adolescent girls in order to reduce levels of anemia prior 
to their initiating childbearing. This strategy has operated through schools 
with the support of the health centres in some states, and in others, has 
operated as part of Kishori Shakti Yojana, the ICDS adolescent girls’ scheme 
(under the Department of Education and DHFW in Gujarat). Iron and folic 
acid tablets are provided under supervision of teachers on a weekly basis. 
Evaluations have shown high rates of compliance and significant 
improvements in haemoglobin levels (Kotecha et al., 2002). This model of 
distributing IFA to adolescent girls is now being adopted in the national 
ICDS programme. 
   
Adolescent Anemia Control Programme 
In June 2000, Adolescent Anaemia Control Programme was initiated 
in Vadodara district, Gujarat, covering over 69000 school girls. The main 
objective of the programme was to improve the poor iron status of the 
adolescent girls. The intervention primarily consisted of weekly IFA 
supplementation to school girls under direct supervision of class teacher and 
nutrition education to the beneficiary girls and teachers with the help of 
Information Education and Communication (IEC) material. Each IFA tablet 
contained 100 mg elemental iron and 0.5 mg folic acid.   
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 Many studies of weekly iron supplementation showed improvement in 
increase in hemoglobin and iron stores. Added Vitamin C to the existing 
weekly iron/folate regiman had some advantages in absorbtion and increase 
in hemoglobin, this should be thoroughly explored and evaluated in the 
context of programs for the prevention and treatment of iron deficiency 
anemia. 
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LITERATURE REVIEW 
 
Iron deficiency anaemia is the most prevalent micronutrient deficiency 
among humans all over the world. Adolescent period is the formative period 
of life when the maximum amount of physical and psychological and 
behavioral changes takes place and they are a particularly vulnerable group 
as their requirements of iron, as well as its losses from the body are high. 
Anaemia during adolescence limits growth and delays the onset of 
menarche, which in turn may lead to cephalopelvic disproportion. Very 
often, in India, girls get married and pregnant even before the growth period 
is over, making anaemia doubly risky. Since the anaemic status of the 
adolescent girls is bound to affect their offspring, care during this period is 
likely to pay rich dividends. 
An intermittent supplementation of iron, that is, weekly once or twice 
could be effective, costs less, has fewer side-effects and would be of 
particular use in a public health programme, if proved to be effective.  
Studies regarding comparing Daily and weekly iron supplementation  
Kianfar H et al (2000)31 in their study conducted in high school girls 
have concluded a weekly iron dose was as effective as a daily dose in 
treating anemia but the daily dose was more effective in improving iron 
stores than a weekly dose in the short run. 
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The study conducted by Young MW(2000)32 in pregnant women of 
Northern Malawi has proved that a weekly iron supplement has similar 
haematologic effects, and less side effect profile, in comparison with a 
standard daily supplement when administered through an existing primary 
healthcare programme, although both regimens are relatively unsuccessful in 
the reduction of anemia prevalence during pregnancy.  
Zavaleta et al (2000)34 have concluded in their study that daily 
supplements led to higher Hb increases than intermittent supplements. Thus, 
both iron supplementation schedules were efficacious in preventing iron 
deficiency in adolescent girls through the school system, and the daily 
schedule was better than the intermittent schedule at increasing Hb values 
and reducing anemia. 
A Chinese study done by Gillespie S (1998)24 has shown that weekly 
iron supplementation with 120 mg was more effective than daily 60mg dose. 
Berger et al (1997)30 in their study have said weekly iron 
supplementation is as effective as 5day per week iron supplementation in 
Bolivian school children living at high altitude. 
Gillespie S (1998)24 in his study has shown that weekly iron 
supplementation with 120mg was more effective than daily 60mg dose 
which in turn was as effective as 120 mg dose. Another study done by the 
same author revealed that weekly 180mg iron was less effective than daily 
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60mg dose. While iron supplements are needed in certain groups and in 
particular regions, increases dietary intakes could be supplied by food 
fortification as well as by individual improvements in intake. A proposed 
meta-analysis is required to finally come to a conclusion about the degree of 
effectiveness of intermittent dosage. 
Study done by Gilgen G et al (2001)33 showed that the rate of increase 
in haemoglobin levels and the correction of anemia is faster in the daily iron 
supplementation group when compared with other groups. Weekly iron is 
equally effective in combating anemia. But the supplementation has to be 
continued on a longer basis in order to combat both anemia and iron 
deficiency. 
Soemantri AG (1997)29 et al in their study conducted in 144 children 
have concluded that the hemoglobin levels in both daily group and weekly 
group increased significantly. 
Berger J (1997)30 in his study said final hemoglobin and its changes 
were similar in both supplemental groups.   
Agarwal K N, Gomber S, Bisht H, Som M35 study showed the daily 
intake for 100 days raised hemoglobin level, which was maintained until 
four months after withdrawal of intervention. Regular weekly administration 
was effective and seems suitable for populations with mild to moderate 
anemia. 
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Studies regarding Weekly iron supplementation  
Beasley et al (2000)28 in their study have said that weekly iron 
supplementation may be effective means of increasing iron stores. 
P.V. Kotecha, S. Nirupam & P.D. Karkar41 study concluded that 
supervised, once a week IFA supplementation to adolescent girls through 
institutions specially schools was found to be an effective intervention to 
reduce anaemia and was scalable within the system.  
Studies regarding iron supplementation along with other micronutrient 
supplementation 
Persson V et al (2000)25 have said programmes to improve iron status 
should consider including both vitamin A prevention programmes and 
deworming. 
Kolsteren P et al (1999)26 in their study on women with anemia have 
showed that addition of vitamin A and zinc to the treatment for anemia can 
increase hemoglobin levels more than with iron alone. 
Ahluwalia (2002)29, Madhavan Nair (2001) in their studies have 
stressed on the aspect of improved intake in the correction of anemia.  
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Studies regarding iron supplementation along with Vitamin C 
supplementation 
Palupi L, Schultink W, Achadi E, Gross R10 showed that the dietary 
intake of Vitamin C along with iron rich sources enhances absorption of the 
iron significantly10. 
A study done by Davidsson L37, it was observed that supplementation 
of 50mg of vitamin C along with iron folate increased the iron absorption to 
7.7% as compared to iron supplementation alone where the iron absorption 
was 1.6% only.   
Pande Rohini, Kuz Kathleen, Wodia Sunayana, Mac Quarrie 
Kerry, Jain Saranga.50  showed supplementation of iron would be effective 
if Vitamin C rich foods consumed along with iron  supplementation. 
A study done by S Mehnaz, S.Afzal, S.Khalil, Z.Khan36 showed the 
difference in the response of mean increase in Hb% of the subjects getting 
Vitamin C supplementation with Fe/folate as compared to those receiving 
only iron/ folate. 
A Study done by Sharma A, Prasad K, Rao KV20  on adolescent 
girls of poor community it was observed that  weekly supplementation of 
vitamin C along with iron/folate had a significant higher increase in 
haemoglobin concentration (0.76g/dl), as compared to weekly iron/folate 
supplementation alone (0.71 g/dl) after three months of supplementation20.  
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STUDY JUSTIFICATION 
In India Iron deficiency anemia prevalence depending on the age and 
sex, reported to range from 38-72 percent, majority of them being women 
and children. The iron deficiency anemia prevalence rate beyond the age of 
six years is higher in girls. This could be due to certain factors such as food 
habits, gender discrimination in food allocation, menstruation and early 
marriage leading to early pregnancy. Estimates suggest that 25-50% girls 
become anemic by the time they reach menarche. Thus in these adolescent 
girls pregnancy only serves to aggravate their pre-existing anemia. 
Iron deficiency anemia is prevalent throughout the world because of 
the inefficient absorption of nonheme iron, which forms the bulk of the iron 
in diet. Absorption of this type impaired by substances in the food like 
phytates which reduces its bioavailability. Ascorbic acid reverses the effect 
of dietary inhibitors and is one of the most powerful known promoters of 
nonheme iron absorption. Though supplementation of iron and folic acid 
remains the cornerstone of the treatment and prevention of anemia, addition 
of vitamin C has its other added advantages.      
We continued to have various health programmes to prevent anemia 
among young children and adolescents for the past several years but we 
continued to have higher prevalence of anemia among them which leads to 
morbidity and mortality during pregnancy and childbirth and after delivery.    
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The major reason for continuation of higher rate of anemia is the 
ineffective regular administration of iron and the daily drug regimen has got 
some adverse effects which hinders continuous intake of iron and also giving 
iron daily for large number of children and adolescents appears to be 
practically not feasible. Indian diets are cereal based and contain high 
phytate content which reduces the bioavailability of iron which is 
significantly improved by added vitamin C in the weekly supplementation 
and also easy to administer. 
This study has been done in view of the efficacy of added vitamin C  
in combating the anemia in adolescent girls to the weekly iron/folate 
regimen. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  43
 
 
 
 
 
 
AIM OF THE STUDY 
  
 
To compare the efficacy of the weekly oral iron/folate versus weekly 
oral iron/folate with Vitamin C supplementation in anemic adolescent school 
girls aged 10 to 14 years 
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MATERIALS AND METHODS 
This is a prospective study. Hypothesis of the study is comparing the 
efficacy of supplementation of weekly iron tablets with and without vitamin 
C which will improve the Hb% in anemic adolescent girls. Based on this 
hypothesis equivalent study design was selected. 
 Four government corporation schools located at Begam Sahib street, 
Triplicane high road, Veera Perumal kovil street, Vannia Teynampet Eldams 
Road affiliated to Government Royappettah Hospital and Kilpauk Medical 
College Hospital selected for this study. Adolescent girls in the age group of 
10 to 14 years studying  6th to 9th  standard were selected for this study. 
Permission from school authorities was obtained. Study was started in 
August 2009 and was conducted till April 2010. 
EXCLUSION CRITERIA: 
1. Children known to have hemolytic anemia, bleeding disorder and 
leukemia. 
2. Known anemic child taking treatment outside. 
3. Children with chronic illness. 
4. Those who are not willing to participate in the trial.  
All these children were excluded from this study. For alpha error 0.05 
and beta error of 0.2 with 95% confidence interval for the outcome i.e., 
increase in Hb% about 95 children are needed in each group. 
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Permission from school authorities were obtained. Ethical committee 
approval from the college was obtained. Informed parental consent was 
obtained from each of the children. 20 microlitre of blood was obtained from 
the children who has given consent (322) by finger prick method and sample 
is estimated for Hb% using cyanmethemoglobin method by adding 5ml 
drabkins solution and results were read by spectrophotometer12.  
Two children from Triplicane high road and 2 child from Eldams road 
school were found to be severely anemic (Hb%<7gm/dl) and referred to 
tertiary care hospital for further management. Children with Hb% >12gm/dl 
(98 children) were excluded from the study. 220 children with mild and 
moderate anemia (Hb% 7 to 12 gm/dl) were totally enrolled for this study and 
after randomization 2 groups were divided with each containing 110 children.                    
Interventions: 
Group A: 110 children receiving weekly oral iron (100mg of elemental 
iron 500mcg of folic acid) tablet for 24 consecutive weeks.  
Group B: 110 children receiving weekly iron tablet (100mg of elemental 
iron 500mcg of folic acid) with Vitamin C 100mg tablet for 24 
consecutive weeks. 
After forming two groups using randomization baseline data of Hb%, 
height and weight were recorded. Anthropometry measurements like weight 
in kg with sensitivity of 100gm, Height in cm using non stretchable tape with 
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sensitivity of 1cm were recorded. Body mass index was calculated using 
NCHS standards (CDC chart) for each of these anemic children. Qualitative 
data was obtained through self-administered questionnaire regarding 
symptoms of anemia from the parents after counseling before the study. The 
symptoms were given a score of 0-Not satisfactory, 1-Average, 2-Good. 
Awareness questions regarding anemia were asked through self-administered 
questionnaire. 
All adolescent girls participating in the study were initially dewormed 
with the tablet Albendazole 400mg and then started on oral supplementation.  
The iron tablets(contains 100mg of elemental iron and 500microgram 
of folic acid) and Vitamin C(100mg) were supplied by the Government. 
Tablets were given to the enrolled girls on every Monday of the week by the 
school teacher in the afternoon half to 1hour after lunch. They were advised 
to take tablets along with water, only after food and never in the empty 
stomach and under supervision. 
Parents were asked to report to the principal investigator through the 
class teacher, if their children developed any problem during the study 
period. Contact phone number of the principal investigator was given to the 
class teacher. 
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Any side effects of the drugs like abdominal pain, vomiting, and loose 
stool were documented as reported by the children or their parents to the 
teacher and later confirmed by the investigator. 
At the end of 12 weeks blood sample was taken for Hb% and 
measured by cyanmethemoglobin method and height and weight were 
recorded. The same method was repeated after 24 weeks. Qualitative data 
was also obtained through self-administered questionnaire regarding anemia. 
Data of 105 children from each group who completed the study were 
available for statistical analysis. Results were tabulated and analysed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  48
ANALYSIS OF OBSERVATIONS 
  
In this study, 346 adolescent girls in the age group of 10-14 years 
studying in corporation schools were taken, of this 322 had given consent for 
screening, and baseline data of height, weight, hemoglobin status obtained. 
Of this 322 subjects, 98(30.43%) had Hb levels >12gm/dl, they were 
excluded from the study. 4 severely anemic girls (<7gm/dl) were referred to 
tertiary care hospital for further management. 220 girls with Hb% <12gm/dl 
were participated in this study they were randomly divided into two groups 
comprising 110 in each group, their baseline data of hemoglobin, height and 
weight were recorded.   
         The girls in Group A were supplemented with iron folic acid 
tablet(100mg elemental iron and 500mcg of folic acid) weekly, and in Group 
B were supplemented with Iron folic acid(100mg elemental iron and 500mcg 
of folic acid) with Vitamin C 100mg weekly for 24 consecutive weeks.  
Finally 105 children in Group A, 105 children in Group B were available for 
statistical analysis. 5 children in each group lost their follow up and dropped 
from the study.   
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 Data were analysed as follows:   
a) Prevalence of anemia 
b) Age distribution  
c) Nutritional status 
d) Awareness about factors regarding anemia 
e) Height at enrollment  
f) Weight at enrollment 
g) Hemoglobin estimation at enrollment 
h) Severity of anemia  
i) Mean hemoglobin distribution   
j) Compliance  
k) Side effects 
l) Outcome analysis  
m) Analysis of associated factors influencing the outcome.  
n) Quality data analysis   
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  A) Prevalence of anemia  
 
Prevalence of anemia of the study population is 69.6% and in that 
1.2% is severely anemic   
 
Prevalence of Anemia at enrollment 
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B) Age distribution 
Table–1: Age distribution 
AGE Group A Group B 
10 5(4.5%) 4(3.6%) 
11 16(14.6%) 16(14.6%) 
12 29(26.4%) 36(32.7%) 
13 43(39.0%) 36(32.7%) 
14 17(15.5%) 18(16.4%) 
Total 110(100%) 110(100%) 
 Majority of the children were in the age group of 12 and 13 years. The age 
distribution was comparable between two groups. 
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C) Nutritional status:    
 
Table-2: Nutritional Status 
Nutritional Status Group A Group B 
Normal 79(71.8%) 78(70.9%) 
Undernutrition 27(24.5%) 25(22.7%) 
Overweight 4(3.6%) 7(6.4%) 
 
Using body mass index (NCHS standard-CDC chart) 
 
Normal nutritional status were seen in 71.8%(79) children in Group A 
and 70.9%(78) of children in Group B. Undernutrition were seen in 24.5% 
(27) of children in Group A and 22.7%(25) of children in Group B. 
Overweight were seen in 3.6% (4) of children in Group A and 6.4%(7) of 
children in Group B. Most of the children were in the normal nutritional 
status range. Both groups were comparable in their nutritional status.   
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D) Awareness about Anemia  
 
Awareness questionnaire was undertaken related to causative factors, 
impact, prevention of anemia on an average  only 7.3% in Group A and 
9.4% in Group B were aware about the factors related to anemia. 
 
Table -4: Awareness Factors about anemia 
S.No 
Factors regarding 
anemia 
Group A 
(Aware) 
Group B 
(Aware) 
N= 
1 Tea/coffee intake 8(7.3%) 7(6.4%) 110/110 
2 Worm infestation 10(9.1%) 12(10.9%) 110/110 
3 Cognitive factors 8(7.3%) 12(10.9%) 110/110 
4 
Delivery related 
complications 
6(5.5%) 11(10%) 110/110 
5 Iron rich foods 9(8.2%) 10(9.1%) 110/110 
6 
Affects adolescent 
girls 
7(6.4%) 10(9.1%) 110/110 
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E) Height at enrollment     
 
Table -5 :Height at enrollment 
 Mean SD 
Group A 142.8 8.3 
Group B 144.2 8.3 
 
The mean height of girls in Group A were 142.8cm and standard deviation 
8.3cm, in Group B were 144.2cm, standard deviation 8.3cm and were 
comparable. 
  
F) Weight at enrollment  
 
Table-6:Weight at enrollment 
 Mean SD 
Group A 33.4 8.6 
Group B 33.3 7.8 
  
Mean weight in Group A were 33.4kg, standard deviation 8.6kg and in 
Group B were 33.3kg, standard deviation 7.8kg and were comparable in both 
groups. 
 
  55
0
10
20
30
40
50
60
70
80
7.1‐8 8.1‐9 9.1‐10 10.1‐11 11.1‐12
Group A
Group B
G) Hemoglobin Estimation at enrollment 
Table-6: Hemoglobin Distribution 
Hb%(gm/dl) Group A Group B 
7.1-8.0 10(9.1%) 10(9.1%) 
8.1-9.0 11(10%) 10(9.1%) 
9.1-10.0 9(8.2%) 11(10%) 
10.1-11.0 64(58.2%) 70(63.6%) 
11.1-12.0 16(14.5%) 9(8.2%) 
Total 110(100%) 110(100%) 
 
No of children with Hb% in Group A and Group B in Hb% between 
7.1 to 8 gm/dl were 10(9.1%), 10 (9.1%) respectively. Children with Hb% 
between 8.1 to 9 gm/dl in Group A and Group B were 11(10%), 10(9.1%) 
respectively. Hb% between 9.1 to 10 gm/dl in Group A and Group B were 9 
(8.2%), 11(10%) respectively. Hb% between 10.1 to 11 gm/dl in Group A 
and Group B were 64(58.2%), 70(63.6%) respectively. Hb% between 11.1 to 
12 gm/dl in Group A and Group B were 16(14.5%), 9(8.2%) respectively. 
Hemoglobin Distribution at Enrollment 
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H) Severity of Anemia   
Table-7: Severity of anemia 
Grades Group A Group B 
Moderate (7 to 9.9 gm/dl) 30(37.5%) 31(39.4%) 
Mild (10 to 11.9 gm/dl) 80(62.5%) 79(60.6%) 
 
According WHO criteria for severity of anemia, moderate anemia was 
seen in 37.5% in Group A, 39.4% in Group B, mild anemia was seen in 
62.5% in Group A, 60.6% in Group B. Both groups were comparable in 
terms of severity of anemia at enrollment. 
 
I) MEAN Hb% DISTRIBUTION 
Table-8: Mean Hb% distribution 
 
Group A Group B 
P value 
Mean SD Mean SD 
Hb% (gm/dl) 10.29 1.14 10.26 1.08 
0.86 
Not significant 
 
Mean Hb% distribution in Group A is 10.29gm/dl, and standard 
deviation is 1.14gm/dl, and in Group B is 10.26gm/dl, and standard 
deviation is 1.08gm/dl. Independent t test showed the p value 0.86 which is 
statistically not significant. Both groups were comparable. 
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J) Compliance    
About 90% of children did not skip even single tablet in both groups, 
5 children in each group lost their follow up due to long absent and 
transferred to other schools.   
 
K) Side effects  
 
Table-9: Side effects 
Side effects Group A Group B 
Vomiting 7 6 
Pain abdomen 4 4 
Loose stool 0 1 
 
Vomiting occurred in 7 children in Group A and 6 children in     
Group B. 4 children in each group had abdominal pain. 1 child in group B 
had loose stools. But all these side effects were only mild and these did not 
interrupt from taking treatment. Side effects were comparable between 
groups. 
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L) OUTCOME ANALYSIS   
Table-10: Increase in Hb% - Group A (WEEKLY IFA ONLY) 
Group A 
Initial At 12 weeks At 24 weeks 
Mean SD Mean SD Mean SD 
Hb% gm/dl 10.29 1.14 11.18 1.07 11.80 0.93 
Mean hemoglobin at the beginning of the study period was 10.2gm/dl 
and its standard deviation was 1.14gm/dl. Mean hemoglobin at the end of 12 
weeks period in Group A was 11.18 and standard deviation was 1.07. Mean 
hemoglobin at the end of 24 weeks was 11.8 and standard deviation was 
0.93.   
 
Table-11: Increase in Hb%- Group B (WEEKLY IFA+VITAMIN C) 
Group B 
Initial At 12 weeks At 24 weeks 
Mean SD Mean SD Mean SD 
Hb% 
(gm/dl) 
10.26 1.08 11.72 0.89 12.54 0.71 
Mean hemoglobin at the beginning of the study period in Group B 
was10.26gm/dl and its standard deviation was 1.08gm/dl. Mean hemoglobin 
at the end of 12 weeks period in Group B was 11.72 and standard deviation 
was 0.89. Mean hemoglobin at the end of 24 weeks was 12.54 and standard 
deviation was 0.71. 
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Table-13: Comparision of Hb% between Group A and Group B at 12 weeks 
 
Group A Group B 
P value (T test) 
Mean SD Mean SD 
Hb%(gm/dl) 11.18 1.07 11.72 0.89 0.000(significant) 
 
At 12 weeks there is a statistically significant (p=0.000 i.e., p<0.05) 
increase in Hb% in Group B compared to Group A. 
 
Table-14: Comparison of Hb% between Group A and Group B at 24 weeks 
 
Group A Group B 
P value (T test) 
Mean SD Mean SD 
Hb% (gm/dl) 11.8 0.93 12.54 0.71 
0.000(p<0.05) 
significant 
 
At 24 weeks also there is statistically significant (p=0.000) increase in 
Hb% in Group B compared to Group A. 
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Table-15: Hemoglobin Gain 
 
Study 
Period 
Group A Group B P value 
(T test) Mean SD Mean SD 
Hb% 
(gm/dl) 
0- 12wks 0.92 0.35 1.47 0.57 
P=0.000 
(significant) 
12-24 wks 0.63 0.35 0.82 0.39 
P=0.000 
(significant) 
0-24 wks 1.56 0.47 2.30 0.69 
P=0.000 
(significant) 
 
 
There is mean gain in hemoglobin level in Group A at 12 & 24 weeks 
were 0.92±0.35, 1.56±0.47, in Group B 1.47±0.57, 2.30±0.69. In between 12 
to 24 weeks 0.63±0.35, 0.82±0.39. But in Group B there is statistically 
significant increase in Hb% gain i.e., p=0.000 (p<0.05)) in the initial 12 
weeks period and also at the end of 24 weeks and also in between 12 to 24 
weeks compare to Group A.  
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Group A-Hemoglobin distribution before & after intervention 
 
 
       
 
 
 
 
X axis: Hb in gm/dl  Y axis: No. of children gained Hb increase 
 
Group B – Hemoglobin distribution before & after intervention 
 
              
 
 
 
 
 
X axis: Hb in gm/dl   Y axis: No. of children gained Hb increase 
SEVERITY OF ANEMIA – GROUP A  
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Table-16: Group A – Severity of anemia 
Grades of Anemia Initial 12 weeks 24 weeks 
Moderate 30(37.5%) 18(17.1%) 9(8.6%) 
Mild 80(62.5%) 57(54.3%) 28(26.7%) 
Normal 0(0%) 30(28.6%) 68(64.8%) 
 
The severity of anemia in Group A decreased to 17.1% from 37.5% in 
moderate, and to 54.3% from 64.5% in mild variety at 12 weeks, and at 24 
weeks it becomes  8.6% in moderate anemia, 26.7% in mild anemia. 
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SEVERITY OF ANEMIA –GROUP B  
 
Table-17: Group B-Severity of anemia 
Grades of Anemia Initial 12 weeks 24 weeks 
Moderate 31(39.4%) 7(6.7%) 4(3.8%) 
Mild 79(60.6%) 34(32.4%) 12(11.4%) 
Normal 0(0%) 64(61.0%) 89(84.8%) 
 
In Group B severity of anemia decreased from 39.4% to 6.7% in 
moderate anemia, 60.6% to 32.4% in mild anemia at the end of 12 weeks, 
and to become 3.8%in moderate and 11.4% in mild anemia at the end of 24 
weeks. 
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No. of Normal children after 24 weeks of supplementation     
Table-18: Group A-children with normal Hb% at 24 week (WEEKLY IFAONLY) 
Period Initial At 24 weeks 
Grade of 
anemia 
N=110 
Moderate 
anemia 
Mild 
anemia 
No 
anemia 
N=105
Moderate 30(37.5%) 9 17 3(2.9)% 
Mild 80(62.5%) - 10 66(62.9%) 
 
In group A at the end of 24 weeks 3(2.9%) & 66(62.9%) girls become not 
anemic from moderate and mild anemia respectively from 30 & 80 at 
enrollment.   
Table-19: Group B-Not anemic at 24 weeks (WEEKLY IFA+VIT.C) 
Period  Initial               At 24 weeks 
Grade of 
anemia 
N=110 Moderate  
anemia 
Mild 
anemia 
No anemia   
  
N=105 Moderate 31(39.4%) 4 8 18(17.1%) 
Mild 79(60.6%) - - 75(71.4%) 
 In group B at the end of 24 weeks 18(17.1%) & 75(71.4%) girls 
become not anemic from moderate and mild anemia respectively from 
31(39.4%) & 79(60.6%) at enrollment.  It shows that conversion into non 
anemic status from low hemoglobin is much better in children taking 
Fe/Folate with Vitamin C.     
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PREVALENCE OF ANEMIA 
 
Table-20: Prevalence of Anemia by Periods of standard 
Period of study Group A Group B N= 
Initial 100% 100% 110 
12 weeks 75(71.4%) 41(39.1%) 105 
24 weeks 37(35.3%) 16(15.2%) 105 
 
Prevalence is decreased at the end of study to 37% in Group A, and 15.2% in 
Group B. 
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Height    
Table-21: Height increase 
 
Initial At 12 weeks At 24 weeks 
Mean SD Mean SD Mean SD 
Group A 142.8 8.3 144.1 8.2 144.9 8.1 
Group B 144.2 8.3 145.6 8.2 146.3 8.3 
P value 0.23 0.73 0.20 
 
There is no statistically significant difference in mean height increase 
between two groups at 12 weeks and 24 weeks of the study period.   
 Height Gain  
Table-22: Height Gain 
 
0-12weeks 12-24 weeks 0-24 weeks 
Mean SD Mean SD Mean SD 
Group A 1.3 0.5 0.8 0.3 2.1 0.8 
Group B 1.5 0.5 0.7 0.4 2.2 0.5 
P value 0.04(significant) 0.09 0.47 
 
There is a statistically significant increase in height gain in Group B 
compared to Group A at the end of 12 weeks period only but at the end no 
significant difference.  
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 Weight    
Table-23: Weight increase 
 Initial At 12 weeks At 24 weeks 
Mean SD Mean SD Mean SD 
Group A 33.4 8.6 34.7 8.5 35.4 8.5 
Group B 33.3 7.8 34.5 8.0 35.4 8.0 
P value 0.91 0.91 0.97 
There is no statistically significant increase in mean weight between 
two groups at 12 weeks and at 24 weeks of the study period.  
  
Weight Gain 
Table-24: Weight Gain 
 
0-12 weeks 12-24 weeks 0-24 weeks 
Mean SD Mean SD Mean SD 
Group A 1.3 0.6 0.7 0.4 2.0 0.7 
Group B 1.3 0.5 0.8 0.4 2.0 0.6 
P value 0.90 0.06 0.34 
There is no statistically significant increase in weight gain in between 
groups during the study period.    
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M) Analysis of associated factors influencing the outcome. 
Table – 25 
 Group A Group B T test  
Mean SD Mean SD 
Weight 35.39 8.53 35.35 8.01 
p = 0.97 
(not significant) 
Height 144.9 8.06 146.3 8.25 
p = 0.20 
(not significant) 
BMI 17.08 3.01 17.35 2.8 
p = 0.84 
(not significant) 
 
 There was no statistically significant difference in weight, height, BMI 
gain between the two groups.  
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N) Quality Data Analysis 
Table - 26 
p value < 0.05 (significant) 
In both groups memory, activity, appetite, sleep pattern, reduction of 
cough symptom significantly improved after supplementation of tablets.  
S.NO DATA  0 1 2 McNemar Bowker test 
1 Memory 
Initial(%) 10 83.3 6.7 
0.000 
Final 1 82.3 16.7 
2 Activity 
Initial 9.5 82.9 7.6 
0.000 
Final 1 78.6 20.5 
3 Games 
Initial 9.5 82.9 7.6 
0.000 
Final 1 78.6 20.4 
4 Studies 
Initial 10 83.3 6.7 
0.000 
Final 1 82.3 16.7 
5 Apetite 
Initial 11 81.9 7.1 
0.000 
Final 0 53.8 46.2 
6 Sleep 
Initial 11 81.9 7.1 
0.000 
Final 0 56.2 43.8 
7 Cough 
Initial 6.7 4.3 89.0 
0.001 
Final 5 3.3 96.2 
8 Overall 
Initial 10.5 82.4 7.1 
0.000 
Final 0 57.6 42.4 
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SUMMARY  
• We followed 220 anemic adolescent school girls aged 10-14 years 
with Hb% level of 7-12gm/dl and were divided into two groups.   
• 110 girls in Group A with weekly once Iron/Folate and 110 girls in 
Group B with weekly Iron/Folate with Vitamin C 100mg were 
supplemented for 24 consecutive weeks. With the baseline Hb%, 
height and weight it was again recorded at 12 and 24 weeks results 
were analysed for 105 children in each group.   
• Awareness questionnaire before the study and quality data before and 
after the study were taken.  
• Study revealed that mean hemoglobin increase noticed in both groups 
but there is statistically significant increase in mean hemoglobin 
noticed in the girls who had supplemented with weekly once iron folic 
acid with Vitamin C. Also the rate of rise in hemoglobin and decrease 
in severity and prevalence of anemia were significant in that group. 
• There is no difference in weight and height gain and BMI in both 
groups. Awareness about anemia was poor and the quality data 
showed better response in both groups and this is subjective 
improvement, it may be influenced by various other factors also.   
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DISCUSSION 
Iron deficiency anemia is the significant problem in adolescent girls 
studying in the schools. A study on adolescents by Mehtha52 revealed that 
63.8% girls were anemic39, another study by Shaw NS40 showed iron 
deficiency was more prevalent in teenage girls, and another study by Cai 
MQ, Yan WY39 showed 61.8% anemia prevalence in adolescent girls. Our 
study showed about 68.3% of young adolescent girls were anemic and the 
prevalence is comparable. In that49.4% of the girls were mildly anemic, 
18.9% were moderate and 1.2% were severely anemic. 
In order to improve the compliance and reduce the intestinal oxidative 
stress, schedules administering hematinics less than once daily have been 
tried. This strategy is based on intestinal mucosal turnover time. It has been 
suggested that saturation of iron binding protein, apoferritin, in the mucosal 
cells is the rate limiting step of the absorption of iron (mucosal block 
theory)35. Since the mucosal removal time in humans is 5-6 days, the 
strategy of weekly iron supplementation has been strongly suggested by 
some worker 11,13 and it also has been done in our study. 
Compliance is one of the important problem in iron supplementation, 
it is better and side effects are less in twice weekly supplementation schedule 
done by Shoba S and Sharda D in adolescent school girls in India44. In our 
  72
study both groups showed better compliance and no major side effects were 
noticed.   
Many studies revealed that weekly iron supplementation in adolescent 
girls had a reasonable increase in hemoglobin concentration.  
Mehta et al.52  reported an increase in the mean haemoglobin level 
from 10.45±1.21 g/dl to 11.99±1.19 g/dl and the halving of the prevalence of 
anaemia from 63.8% after weekly supplementations of iron and folic acid for 
25 weeks, which were comparable with daily supplementation.  A study done 
by Cai MQ, Yan WY39 showed that weekly supplementation of iron 
improved hemoglobin concentration in adolescent girls.  A study done by 
Kotecha et al.41 showed that weekly iron supplementation in adolescent girls 
had improvement in both hemoglobin and serum ferritin levels. In our study 
weekly once IFA supplementation showed comparable results with a mean 
Hb% increase from 10.29±1.14 to 11.8±0.93 g/dl at the end of 24 weeks. 
The dietary intake of Vitamin C along with iron rich sources enhances 
absorption of the iron significantly22, 23. In a study done in Tamilnadu by 
Swarnalatha A, Yegammai C concluded that adolescent girls showed better 
absorption of iron if it is given with absorption enhancers like Vitamins A 
and C than iron alone19. In a study by Davidsson L.37 it was observed that 
supplementation of 50mg of vitamin C along with iron folate increased the 
iron absorption to 7.7% as compared to iron supplementation alone where 
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the iron absorption was 1.6% only. In our study 100mg Vitamin C is added 
to the weekly regimen and showed comparable results.  
A study done by S Mehnaz, S.Afzal, S.Khalil, Z.Khan36 showed the 
difference in the mean increase in Hb% response of the subjects getting 
Vitamin C supplementation with Fe/folate as compared to those receiving 
only iron/ folate. 
A study by Sharma et al.,20 done on adolescent girls of poor 
community it was observed that  weekly supplementation of vitamin C along 
with iron/folate had a significant higher increase in haemoglobin 
concentration (0.76g/dl), as compared to weekly iron/folate supplementation 
alone (0.71 g/dl) after three months of supplementation.  
In our study the weekly iron supplementation with added Vitamin C 
showed that increase in hemoglobin concentration of 2.30±0.69g/dl 
compared to a hemoglobin increase of 1.56±0.47g/dl in weekly once iron 
folate supplementation group at the end of 24 weeks period and it was 
significant, and it also showed at the end of 12 weeks also there is a 
significant increase in concentration of  hemoglobin(0.82±0.39g/dl) in the 
weekly IFA+Vitamin C supplementation group. The prevalence and severity 
is also significantly reduced in the added Vitamin C group.   
In our study rate of rise of hemoglobin was more in the girls who had 
lower hemoglobin level before supplementation in the weekly IFA with 
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Vitamin C group as showed in the study done by S Mehnaz, S.Afzal, 
S.Khalil, Z.Khan36 . 
Weekly supplementation is superior to daily supplementation on 
height gain among school children in Thailand done by Rassamee 
Sungthong, Ladda Mo-suwan, Virasakdi Chongsuvivatwong and Alan F 
Geater45. In our study there is height gain occurred in both groups, slight 
marginal increase occurred in Fe/folate with Vitamin C  group in the 12 
weeks period but no significant height gain difference noticed between the 
groups at end of the study. 
In the study done by Shubadha J. Kanani and Rashmi H. Poojara38 has 
showed significant weight gain noticed in the adolescent school girls of 10-
14 years. In our study also weight gain noticed in both groups in 12 weeks 
and 24 weeks period but there is no significant difference in weight gain 
noticed between the groups.  
Study on the impact of iron and folic acid supplementation along with 
Vitamin C on  haemoglobin Status of adolescent girls in an ICDS block in 
2008 report showed when IFA supplementation was given with vitamin C 
bi-weekly to the subjects compared to once weekly and daily iron with and 
without vitamin C, the increment of hemoglobin observed was maximum. 
The increment in mean height was 1.0 cm at three months and 0.2 cm at six 
months of supplementation. The mean weight of the subjects increased by 
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2.2 kg at three months and it remained the same at six months of 
supplementation. The haemoglobin increased by 2.5 per cent at three months 
and 0.2 percent at six months of supplementation. In our study we used 
weekly once supplementation it showed comparatively better results. 
From the Indian Institute of Health and Family Welfare, Annual 
Report, 2001-200251 it was evident that the results of midterm survey 
revealed that weekly IFA supplementation to school going girls, under 
teacher’s supervision, for preceding six months together with IEC 
intervention resulted in a significant increase in haemoglobin levels, 
indicating the feasibility of this approach. In our study also showed that 
added Vitamin C to the weekly IFA regimen under supervision is feasible in 
improving the hemoglobin level significantly.  
Qualitative analysis showed that significant improvement in memory, 
physical activity, appetite etc., in both the groups after intervention. But this 
is only subjective and several other factors may play a role in this outcome. 
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CONCLUSION 
 
1. Both weekly supplementation of Fe/Folate and Fe/Folate with Vitamin 
C group showed increase in mean hemoglobin levels in the anemic 
children. 
2. Increment in Hb levels of subjects with addition of Vitamin C to 
weekly iron/folate supplementation was more effective than that with 
supplementation of iron/folate alone at the end of 12 and 24 weeks. 
3. Prevalence of mild and moderate anemia decreased in both groups but 
Fe/Folate with Vitamin C showed dramatic response.  
4. There is a gain in height in both groups but there is slightly increased 
gain noticed in added Vitamin C group at the end of 12 weeks.  
5. Weight gain showed no difference in between groups.  
6. Compliance is better in both groups and side effects are also minimal.  
7. Nutrition education and IEC about anemia in schools is a must and to 
be integrated in these approaches to reduce the anemia effectively.  
8. Weekly once Fe/Folate with Vitamin C supplementation showed 
better hemoglobin increment in short duration in the anemic children. 
9. Suggested that a public health approach consisting of once weekly 
distribution of iron/folate with added Vitamin C through schools under 
supervision may be a better strategy than giving weekly iron/folate 
alone in adolescent girls to combat anemia.       
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ANNEXURE – I 
 
Data Collection Form 
Name:         Date: 
Age:  
Date of birth:   
Sex:  
Class:  
School:  
Group:                 A [weekly IFA only]     /    B [weekly IFA with Vitamin C]  
Anthropometry:   At Enrollment       At 12 Weeks      At 24 Weeks  
Height (cm):  
Weight (kg):  
Body Mass Index:  
Nutritional status:  Undernutrition / Normal / Overweight 
(Based On NCHS Standard)  
Puberty Status: 
Investigation:                                      
 At Enrollment 12 Weeks 24 Weeks 
Hb % in gm/dl    
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ANNEXURE – II 
 Qualitative Data 
1. How is the memory power of your child? 
Not satisfactory / Average / Good 
 2. Does your child is physically very active? 
  Not satisfactory / Average / Good 
3.       Activities of your child in outdoor games? 
Not Satisfactory / Average / Good 
 4. How is your child in their studies? 
Not Satisfactory / Average / Good 
 5. How is the appetite of your child? 
Not Satisfactory / Average / Good 
6. How is the sleep pattern of your child? 
Not Satisfactory / Average / Good 
7. Does your child have frequent attacks of cough? 
Yes / Occasionally / No 
8.   Overall performance of your child? 
Not satisfactory / Average / good 
 Date: 
 Place:      Signature of parent  
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ANNEXURE – III 
 
Awareness Questionnaire about Anemia 
1. Does anemia affect adolescent girls? 
Yes / No 
2. Does worm infestation lead to nutritional anemia? 
Yes / No 
3. Do you know about iron rich foods? 
Yes / No 
4. Does tea intake affect absorption of iron? 
Yes / No 
5. Does anemia cause cognitive impairment? 
Yes / No 
6. Does anemia lead to delivery related complications in pregnant 
women? 
Yes / No 
 
Name of the student: 
Date: 
Place:       
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ANNEXURE - IV 
Cyanmethemoglobin (Hemoglobin cyanide) method  
 
It is the WHO recommended method for determining the Hb 
concentration. 
 
Basis of the method is dilution of blood in a solution containing 
potassium cyanide and potassium ferricyanide. Haemoglobin, 
methemoglobin, and carboxyhemoglobin but not sulphemoglobin are 
converted to HiCN. The absorbance of the solution is then measured in 
spectrometer at a wave length of 540nm or a photoelectric calorimeter with a 
yellow green filter. 
 
Diluents: 
Drabkins cyanide ferricyanide solution with PH of 7.0-7.4 
Pottassium ferricyanide (0.607 mmol/l) 200mg  
Potassium cyanide (0.768 mmol/l) 50mg 
Pottassium dihydrogen phosphate (1.029 mmol/l) 140mg  
Nonionic detergent 1ml  
Distilled or deiodinised water 1 litre   
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Method  
Make a 1 in 201 dilution of blood by adding 20ul of blood 5ml of 
diluents. After being allowed to stand at room temperature for at least 5 min, 
pour test sample into the cuvette and read the absorbance in a 
spectrophotometer at 540nm or in a photoelectric calorimeter.  
 
Advantages  
 
1) It allows the direct comparison with HiCN standard after dilution so 
batching is possible.  
 
2)  All forms of hemoglobin except sHb are readily converted to HiCN   
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ANNEXURE - V 
WEEKLY ORAL IRON EFFICACY STUDY INFORMED CONSENT 
FORM – SCREENING 
elj;Jk; Kiw : 
 ,e;j Ma;tpy; gq;F nfhs;tjw;F cq;fs; Foe;ij 10 Kjy; 14 
taJilatuhf ,Uf;f Ntz;Lk;. cq;fs; Foe;ij cly; eyj;ij ghpNrhjpf;f 
mtHfs; KO kUj;Jt Fwpg;Gfs; Nfl;lwpe;J nfhs;sg;gLk;. Kf;fpakhf cq;fs; 
Foe;ijf;F ,uj;j Nrhiff;fhf VNjDk; kUe;J cl; nfhs;Sjy;> ePz;l ehs; 
tpahjp> ,uj;jg;Nghf;F Neha; Nghd;wit ,Ug;gpd; ,e;j Ma;Tf;F 
jFjpapy;yhjtuhtH. 
 NkYk; cq;fs; Foe;ij ,e;j Ma;tpy; gq;F nfhs;s Ntz;Lnkd;why; 
,uj;jg; ghpNrhjid  (Hb %) nra;a Ntz;Lk;. ,e;j ,uj;j ghpNrhjidapy; cq;fs; 
Foe;ijf;F Hb msT 7 gm / dl fPNo kpfTk; ghjpf;fg;gl;bUe;jhNyh 12 gm / dl f;F 
NkNy ,Ue;jhNyh Ma;tpy; gq;F nfhs;s KbahJ. cq;fs; Foe;ijapd; 
Ma;Tfs; gw;wpa tptuq;fis njhpe;J nfhs;s Ntz;Lnkd;why; jaT nra;J 
cq;fSila Nfs;tpfis Nfl;fTk;. ,uj;jj;jpy; Hb msT 7 gm / dl Fiwthf 
,Ug;gpd; jFe;j kUj;Jt MNyhridfs; ,ytrkhf toq;fg;gLk;. ,e;j 
ghpNrhjidapy; cq;fs; Foe;ij gq;F nfhs;tjhy; ,uj;j Nrhif cs;sjh vd;W 
njhpatUk;. 
,lh;fs; : ,uj;jk; vLf;Fk; NghJ rpwpa typ Vw;gLk;. 
 ,t;tha;tpy; gq;FngWk; vy;yh egh;fSila tpguq;fSk; ,ufrpakhfg; 
ghJfhf;fg;gLk;. xOf;fk; njhlh;ghd FOtpdUk;> ,e;j Ma;it elj;Jfpd;w 
egh;fs; kl;Lk; cq;fSila Foe;ijapd; Fwpg;Gfis ghh;itapl mjpfhuk; 
cs;stu;fs;. cq;fs; Foe;ij ,e;j Ma;tpy; njhlh;e;J ,U;f;f Ntz;Lk; vd;gJ 
fl;lhaky;y> ve;j Neuj;jpYk; cq;fs; gq;fspg;ig epWj;jpf; nfhs;syhk;. cq;fs; 
Foe;ij ,e;j Ma;tpy; gq;F nfhs;stpy;iy vd;whNyh my;yJ ,ilapy; 
epWj;jpf; nfhs;s KbT nra;jhNyh mjw;fhf ePq;fs; ve;jtpj mguhjKk; fl;lj; 
Njitapy;iy. 
 cq;fs; Foe;ijf;F nra;ag;gLfpd;w midj;J kUj;Jt ghpNrhjidfSk; 
,ytrkhf nra;ag;gLk;. ,e;j njhluha;tpy; nra;ag;gLfpd;w nra;Kiwfspdhy; 
Vw;gLk; gf;f tpisTfSf;F kUj;Jt cjtp nra;ag;gLk;. ve;jtpj e\;l <Lk; 
jug;gl khl;lhJ vd;gijAk; mwpe;J nfhz;Nld;. 
1. ehd; ,e;j     Njjpapl;l jfty; gbj;ij ed;whfg; gbj;J> 
gbj;Jf; fhl;b vLj;Jiuj;jij Ghpe;J nfhz;Nld;. vdf;F Nfs;tp Nfl;Fk; 
tha;g;Gk; fpilj;jJ.  
2. ,e;j Ma;tpy; ehd; vd;Dila Ra mwpNthL gq;F nfhs;fpNwd;. NkYk; 
Ma;tpypUe;J ve;j tpj fhuzKk; juhky; kUj;Jtg; ghpNrhjidapypUe;J 
ehd; tpyfpf; nfhs;syhk;. ,jw;F rl;lhPjpahd ve;j nraYk; cl;gLj;jhJ. 
3. Ethics FOtpd; mq;fj;jpdh;fNsh> ,e;j Ma;it elj;Jgth;fNsh 
vd;Dila kUj;Jt Ma;tpd; midj;J tptuq;fisAk; vd;Dila 
mDkjpapd;wp ghh;f;fNth> gbf;fNth chpikAs;stHfshth;. ehd; ,e;j 
Ma;tpypUe;J tpyfpf; nfhz;lhYk; $l vd;Dila tptuq;fis mth;fs; 
mwpe;J nfhs;s xj;Jf; nfhs;fpNwd;. vd;Dila tptuq;fs; midj;Jk; 3 
tJ egUf;Nfh> my;yJ gj;jphpf;ifapy; ntspapLtjw;Nfh Kay khl;Bh;fs; 
vd ek;GfpNwd;. 
4. ,e;j Ma;tpypUe;J ngwg;gl;l Gs;sp tptuq;fisNah my;yJ KbTfis 
gad;gLj;j $lhJ vd;W fl;Lg;gLj;j khl;Nld;. 
5. vd; Foe;ijia ,e;j kUj;Jt Ma;tpw;F gq;F nfhs;s ghpg+uzkhf 
rk;kjpf;fpNwd;. 
 
ifnahg;gk;       
ngah;        
Foe;ijapd; ngah;      
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ANNEXURE - VI 
WEEKLY ORAL IRON SUPPLEMENTATION EFFICACY STUDY 
njhptpf;fg;gl;l xg;Gjy; gbtk; 
  
ekJ ehl;by; Vwf;Fiwa 50% Foe;ijfSf;F ,uj;j Nrhif ghjpg;G 
cs;sJ. ,Uk;G rj;J FiwNt ,jw;F kpf Kf;fpa fhuzkhFk;. Foe;ijapd; 
mwpT tsh;r;rp> cly; MNuhf;fpak; kw;Wk; euk;G kz;ly tsh;r;rpapy; ,uj;j 
Nrhif ghjpg;ig Vw;gLj;j ty;yJ. NkYk; ,jdhy; Neha; vjpHg;G rf;jp FiwT> 
clypy; Nrhh;T Nghd;w gy cly; ey FiwghLfs; Vw;gLk;. 
,e;j Ma;tpd; %yk; ,uj;j Nrhif kUj;Jtj;jpw;F thuk; xUKiw ,Uk;G 
rj;J khj;jpiu kw;Wk; itl;lkpd; rp toq;Fjy; Kiw kw;Wk; thuk; xU Kiw 
,Uk;G rj;J khj;jpiu kl;Lk; toq;Fjy; Kiw Mfpa ,uz;L KiwfisAk; 
jpwdha;T nra;ag;gLk;. ,e;j Ma;tpd; %yk; fpilf;fg;ngWk; jfty;fisf; 
nfhz;L ,uj;j Nrhif fistjw;fhd topKiwfis Muhag;gLk;. 
,e;j Ma;tpy; gq;F nfhs;s jq;fs; tuNtw;fg;gLfpwPh;fs;. ,e;j Ma;tpd; 
nghUl;L jq;fs; Foe;ijapd; vil> cauk;> ,uj;j ghpNrhjid (Hb%) Mfpait 
Ma;tpd; Muk;g epiyapYk; 3> 6 khj ,WjpapYk; Nkw;nfhs;sg;gLk;. ,jw;fhf 
jq;fs; Foe;ijaplkpUe;J 0.02ml msT ,uj;jk; Njitg;gLk;. 
kUj;Jt Ma;T kw;Wk; ghpNrhjidapy; jq;fs; Foe;ijf;F ,uj;jNrhif 
(Hb 7-12 gm%) cs;sJ fz;lwpag;gl;lhy; kl;LNk ,e;j Ma;tpw;F njhlh;e;J 
mDkjpf;fg;gLtu;. Nkw;gb Nrhjidapy; jq;fs; Foe;ijf;F ,uj;j Nrhif 
cs;sJ fz;lwpag;gl;lhy; njhFjp 1 (24 thuq;fSf;F thuk; xU Kiw ,Uk;G 
rj;J khj;jpiu kl;Lk; ngWk; Foe;ijfs;) my;yJ njhFjp 2 (6 thuq;fSf;F 
thuk; xU Kiw ,Uk;G rj;J khj;jpiu kw;Wk; itl;lkpd; rp khj;jpiu ngWk; 
Foe;ijfs;) ,tw;wpy; xd;wpy; tFf;fg;gl;L ,Uk;G rj;J khj;jpiufs; toq;fg;gLk;. 
12> 24 thu Kbtpy; kPz;Lk; xU Kiw Nkw;fz;l ghpNrhjidfs; jq;fs; 
Foe;ijfSf;F nra;ag;gLk;. ,e;j Ma;tpy; jq;fspd; gq;fspg;ghy; NkNy 
Fwpg;gpl;l ,uz;L tif kUj;Jt Kiwfis jpwdha;T nra;a totFf;Fk;. 
,e;j Ma;tpy; gq;Nfw;gjhy; cq;fs; Foe;ijf;F ,uj;j Nrhif cs;sJ 
fz;lwpag;gl;L mjw;fhd kUj;Jt rpfpr;irAk; ,ytrkhf mspf;fg;gLk;. 
ghpNrhjidapy; jq;fs; Foe;ijf;F Vw;gLk; f\;lq;fs; ahnjdpy; ,uj;jk; vLf;Fk; 
NghJ rpW typ kl;LNk. ,e;j Ma;tpy; cq;fs; Foe;ij gq;Nfw;gJ kdKte;J 
ePq;fshfNt Kd;G te;jhYk;> ,e;j Muha;r;rpapy; fl;lhak; njhlHe;J ,Uf;f 
Ntz;Lk; vd;wpy;yhky;> ePq;fs; ve;j Neuj;jpYk; cq;fs; Foe;ijia ,t;tha;tpd; 
,Ue;J tpyfpf; nfhs;syhk;. ePq;fs; ,e;j Muha;r;rpapy; ,y;iy vd;whNyh my;yJ 
Ma;tpypUe;J tpyfpf; nfhs;sj; jPu;khdpj;jhNyh mjw;fhf cq;fsplkpUe;J e\;l 
<L vJTk; Nfl;fg;gl khl;lhJ. 
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ghpNrhjidahsh;> cq;fs; Foe;ijia ,e;j Ma;tpy; gq;F ngwhky; 
epWj;Jk;gb Nfl;fTk; tha;g;Gs;sJ. ,J vg;NghJ elf;Fk; vdpy; ePq;fs; ,e;j 
Ma;T elf;Fk; fhyj;jpy; NtW VjhtJ ,Uk;G rj;J kUj;J vLj;Jf; 
nfhz;lhNyh my;yJ Kjd;ik ghpNrhjidahsh; ,e;j Ma;tpy; njhlh;e;J 
,Ue;jhy; Foe;ijapd; cly; eyj;jpw;F ey;yjy;y vd;W ek;gpdhYk; 
epWj;jg;gLtPh;fs;. 
 Confidentiality : jhdhf Kd;te;J ghpNrhjidapy; gq;FngWk; egh;fspd; 
tptuq;fs; midj;Jk; ,ufrpakhf ghJfhf;fg;gLk;. 
 cly; ghpNrhjid kw;Wk; ,uj;jg;ghpNrhjid fl;lz vJTkpd;wp ,ytrkhf 
nra;ag;gLk;. Ma;T njhlq;Fk; Kd;ghfNth my;yJ ele;J nfhz;bUf;Fk; 
rkaj;jpNyh cq;fSf;F VjhtJ re;Njfq;fs; ,Ue;jhy; Nfl;fyhk;. mg;gb 
Ma;itg; gw;wpf; Nfl;Fk; Nfs;tpfs; kUj;Jtiuf; Nfl;fyhk;.  
 ,e;j njhluha;tpy; nra;ag;gLfpd;w nra;Kiwfspdhy; Vw;gLk; gf;f 
tpisTfSf;F kUj;Jt cjtp nra;ag;gLk;. 
1. ehd; ,e;j     Njjpapl;l jfty; gbj;ij ed;whfg; gbj;J> 
gbj;Jf; fhl;b vLj;Jiuj;jij Ghpe;J nfhz;Nld;. vdf;F Nfs;tp Nfl;Fk; 
tha;g;Gk; fpilj;jJ.  
2. ,e;j Ma;tpy; ehd; vd;Dila Ra mwpNthL gq;F nfhs;fpNwd;. NkYk; 
Ma;tpypUe;J ve;j tpj fhuzKk; juhky; kUj;Jtg; ghpNrhjidapypUe;J 
ehd; tpyfpf; nfhs;syhk;. ,jw;F rl;lhPjpahd ve;j nraYk; cl;gLj;jhJ. 
3. Ethics FOtpd; mq;fj;jpdh;fNsh> ,e;j Ma;it elj;Jgth;fNsh 
vd;Dila kUj;Jt Ma;tpd; midj;J tptuq;fisAk; vd;Dila 
mDkjpapd;wp ghh;f;fNth> gbf;fNth chpikAs;stHfshth;. ehd; ,e;j 
Ma;tpypUe;J tpyfpf; nfhz;lhYk; $l vd;Dila tptuq;fis mth;fs; 
mwpe;J nfhs;s xj;Jf; nfhs;fpNwd;. vd;Dila tptuq;fs; midj;Jk; 3 
tJ egUf;Nfh> my;yJ gj;jphpf;ifapy; ntspapLtjw;Nfh Kay khl;Bh;fs; 
vd ek;GfpNwd;. 
4. ,e;j Ma;tpypUe;J ngwg;gl;l Gs;sp tptuq;fisNah my;yJ KbTfis 
gad;gLj;j $lhJ vd;W fl;Lg;gLj;j khl;Nld;. 
5. vd; Foe;ijia ,e;j kUj;Jt Ma;tpw;F gq;F nfhs;s ghpg+uzkhf 
rk;kjpf;fpNwd;. 
ifnahg;gk;       
ngah;        
Foe;ijapd; ngah;      
 
Signature of the Investigator :     Date : 
Signature of the Witnesses :     Date :  
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SL.NO GROUP          NAME AGE S.E.STATUS PUB.ATTA HT1 WT1 BMI 1 HT2 WT2 BMI2 HT3 WT3 BMI3 HB1 HB2 HB3
1 A SHEELA 10 3  142 53 26.28  143.5 54 26.22  144.5 54 25.86 10.8 12.2 12.5
2 A REVATHY 10 4  132 23 13.2  133.8 23.5 13.13  134.6 24 13.25 10.6  11  11.5 
3 A RUTHRA 10 3  131 22 12.82  133.4 24 13.49  133.9 25 13.94 11.3  12 12.3 
4 A A.PRIYA 10 4  121 20 13.66 123.7 22 14.38 124.8 22 14.13 10.4  11.6 12 
5 A SARATHA 10 4 y  145 33 15.7 145.5 34 16.06 147 35 16.2 11.5  12.5  12.5 
6 A JEGATHEESWARI 11 4  130 28 16.57  131.7 29 16.72  133 29 16.39 9.1  11.3  12
7 A V.NANDHINI 11 4  126 22 13.86  127.3 23 14.19 128.5 23.5 14.23 10.2  11  12 
8 A SHIFANA 11 3  134.5 26 14.37 136 27 14.6  137.3 28 14.85 11.4  12 13 
9 A SANDHYA 11 4  131 30 17.48  132.8 32 18.14 133.8 33 18.43 11.2  12.2  12.8
10 A LAKSHMI 12 4  132 26 14.92 134 27 15.04  135.5 27.5 14.98 11.4  11.5  12.4 
11 A ABIRAMI 11 3  134  25 13.92  136 26 14.06  137.5 27 14.28 10.7 12.2 12.5 
12 A A.NANDHINI 11 3 126 23 14.49 127.4 24 14.79 127.6 24.5 15.05 11.5 12 12.5
13 A MUTHALAGHI 11 4  138.7  25 13  139.2  25 12.9 140 26 13.27 10.8 11.8 12.3 
14 A GIRIJA 12 4  144 36 17.37 145.8 37 17.41  146.5 37.5 17.47 10.7 11.7 12.4 
15 A KUZHALI 13 3  144 32 15.43 145.8 34 15.99  146 34.5 16.19 9 .1 10.5  11 
16 A KALAISELVI 14 3 y  154 43 18.13  156.2 45 18.44 157.1 45.5 18.44 11.5  12 12 
17 A SATHYA 13 3 y  147 33 15.27  147.6 35 16.07 148 35 15.98 10.7  11.5  11.3
18 A REKHA 13 3 y  151 41 17.98  151.6 41.5 18.06  151.8 42 18.23 10.8 11 11.5 
19 A SHANTHI 12 4 y  144 40 19.29 145.5 41 19.37 146 41 19.23 10.2  11.5  12 
20 A SELVI 12 4  140 29 14.8  141  30 15.09  142 30 14.88 10.8 12  12
21 A SRIPRIYA 12 4  131 31 18.06  132 33 18.94  133.5 33.5 18.8 10.7 11.5  12 
22 A YASODHA 12 4 y  150 47 20.89  151.2 49 21.43  151.5 49.5 21.57 9.8  10  12 
23 A RAMYA 11 4  133 27 15.26  134.7 29 15.98  136 30 16.22 8.6  9.2 9.8 
24 A NEELU 11 4  135 30 16.46  136.5 33 17.71  137.3 33.5 17.77 10.8 12  12.8 
25 A MAHALAKSHMI 12 4 y  139 25 12.94  141  28 14.08  141.5 28.5 14.23 11  12.2 12.8 
26 A RAJI 12 3 y  153 40 17.09  154 40.5 17.08 155 41 17.07 10.8 12  12.8 
27 A S.NANDHINI 11 4  136 29 15.68  137.9 31 16.3  139 31.5 16.3 10.8 12 12.5 
28 A GAYATHRI 12 4  134 26 14.48  136.4 28 15.05 137.2 29 15.41 10.7 12  12.2 
29 A ANJALI 13 4  139 28 14.49  140 29 14.8  140.8 30 15.13 11.5  12  12.5 
30 A GIRIJA 12 4 y  141 29 14.59  142.3 29 14.32 143.5 30 14.57 10.6  11.8  12.5 
MASTER CHART - GROUP A (WEEKLY ONCE IRON / FOLIC ACID ONLY)
SL.NO GROUP          NAME AGE S.E.STATUS PUB.ATTA HT1 WT1 BMI 1 HT2 WT2 BMI2 HT3 WT3 BMI3 HB1 HB2 HB3
31 A MONISHA 12 4  130 21 12.43  131.2 23.5 13.65 132.5 24 13.67 11  12  12.5 
32 A R.NANDHINI 12 4 y  147 35 16.2 149.5 36 16.11 150 37 16.44 10.4  11.5  11.7 
33 A NITHYA 12 4  141 27 13.6  142.2 29.5 14.59  143.5 29 14.08 11.5  12  12.5 
34 A VANAJA 13 3 y  148.5 35.5 16.1  149.5 37 16.55 150 37.5 16.67 10.8 11.8  12.6 
35 A SUDHA 12 5  142 30 14.9 143.1 31 15.14  144 31 14.95 8.5  10.4  11 
36 A ASHAVANI 13 4  140 31 15.8 141.1 33 16.58 142 33 16.37 11  11.8 12.4 
37 A MOHANAPRIYA 12 4 y  144 31 14.95  145.4 32 15.14  146.5 32.5 15.14 10.7 11.8  12.5 
38 A SUJATHA 13 5  143 29 14.2  145.5 31 14.64 146 32 15.01 8.1  9 9.8 
39 A SARITHA 12 5  144 35 16.9 145.2 36 17.08 145.8 36 16.94 8.6  10.2 11.2 
40 A DEEPA 13 5 y  136 24 13  136.8 25 13.36  137.8 26 13.69 7.2  8.2 9.2 
41 A NATHIYA 13 5 y  153 39 16.7  154.2 40 16.82 154.8 41 17.11 8.0  8.9 9.8
42 A KANJAMMAL 13 4 y  151 34 14.9  152 35 15.15 153 35.5 15.17 9.2  9.9 10.6 
43 A PRABHAVATHI 12 3 y  152 42 18.2 152.6 42.5 18.25  153.5 43 18.25 10.7 11.8  12.2 
44 A PARIMALA SUJATHA 12 4  152 37 16 153 38 16.23 153.5 39 16.55 10.5  11.3 11.9 
45 A ANANDHI 14 3  150 36 16 151 37 16.23 151.5 38 16.56 10.5 11.2  11.9 
46 A DIVYA 13 4  147 35 16.2  147.5 37 17.01  148.5 38 17.23 8.2  9.4  10.4 
47 A JANAKI 14 4  153 42 17.9  154 43 18.13  154.5 43.5 18.22 10.7 11.5  12.2 
48 A LATHA 13 4 y  163 70 26.4  164 71 26.4 165 72 26.45 9.5  10.5 11.6 
49 A NISHAKUMARI 13 5  143 32 15.65 143.5 33 16.03 144 34 16.4 8.1  9.6 10.6 
50 A PRIYANKA 12 5  136 29 15.7  137.5 30 15.87 138 31 16.28 8.6  9.4  10.2 
51 A PREMA 13 4  137.5 25 13.22  139.3 26 13.4  140.8 27 13.62 8  9.2 10.2 
52 A SAVITHRI 13 5  130 20 11.8  131.5 22 12.72 132.5 22.5 12.82 10.7 11.5  12.2 
53 A USHA 12 3  145 39 18.55  147 41 18.97  148 41.5 18.95 11 11.8  12.5 
54 A UMA 13 4  132.5 26 14.81  134.2 27 14.99  135.4 27.5 15 9.6  10  11.2 
55 A VICITHRA 14 5 y  151 34 14.91  152.2 35 15.11 153 36 15.38 8  9.2  10.2 
56 A VARALAKSHMI 13 4  130 28 16.57  131.8 29 16.69 132.8 30 17.01 8.5  9.5  10.2 
57 A YUVARANI 13 5  138.5 27 14.08  140 28 14.29 141 29 14.59 8.6  9.6  10.8 
58 A POOVARASI 13 4  152 36 15.58  153.5 37 15.7  154.5 38 15.92 10.9 11.6 12.4 
SL.NO GROUP          NAME AGE S.E.STATUS PUB.ATTA HT1 WT1 BMI 1 HT2 WT2 BMI2 HT3 WT3 BMI3 HB1 HB2 HB3
59 A RISWANA 13 3 y  151.5 36 15.68  153.5 38 16.13 154.5 39 16.34 7.9  9.1 10.2 
60 A PRIYA 13 4  148 36 16.44  149.2 37 16.62 150 38 16.89 10.5  11.2  12.2 
61 A LAVANYA 14 4  146  33 15.48 147.8 34.5 15.79 148.5 35.5 16.1 10.8 11.8  12.4 
62 A DHARANI PRIYA 13 3  149 37 16.67 150 39 17.33  151 40 17.54 11.6  12.2  12.5 
63 A UMAMAHESWARI 14 3  145 44 20.93  146 45 21.11  146.8 45.5 21.11 9.8  10.8  11.5 
64 A PRIYA 14 4  149 35 15.77  150  36 16  151 36.5 16.01 10.7 11.7 12.5 
65 A NAGALAKSHMI 13 4 y  146.5 32 14.91 147.1 34 15.71  147.9 35 16 10.6 11.8 12.5 
66 A KEERTHANA 13 4 y  153 43 18.37  153.8  44 18.6 154.5 45 18.85 11  11.8  12.5 
67 A VINODHINI 13 5 y  141 34 17.1  142.5 36 17.73 143.5 36.5 17.73 7.8  9.2  9.9 
68 A LAVANYA 14 5  145 39 18.55  145.3 40 18.95 146 40 18.77 7.6  8.8 9.9 
69 A PARAMESWARI 13 4  151 32 14.03  152.3 34.5 14.87 153.6 35 14.83 10.8  11.8 12.5 
70 A JEEVITHA 12 4  141.5 27 13.48 142.9 28.5 13.96 143.9 29 14 10.7 11.8  12.5 
71 A DEEPA 14 4 y  152 51 22.07 152.3 52 22.42  153 52.5 22.43 11.4  11.8 12.3
72 A SIVAGAMI 14 4  158 37 14.82  158.7 37 14.69  159.6 37.5 14.72 10.7 12.0  12.5 
73 A JESI 14 4  158 48 19.23 159 49 19.38 159.5 49.5 19.46 11.2  11.9  12.5 
74 A PAVITHRA 13 4  135 27 14.81  136.2  27.5 14.82 137 28 14.92 11.2  11.8 12.4 
75 A JEYACHITHRA 12 4  146 29 13.6  146.9  30 13.9  147.6 31 14.23 10.8 12 12.5 
76 A VANITHA 13 4 y  142.5 43 21.18  143 44 21.52 143.5 44.5 21.61 11.6  12.2 12.8 
77 A HAJEERA 11 3 138 23 12.08 139.8 24.5 12.54 140.5 25.5 12.92 11 11.8 12.5
78 A RESHMA 11 4 129 26 15.62 130.2 27 15.93 130.5 27.5 16.15 10.2 11.3 11.8
79 A NAJMA 11 3 130 25 14.79 131.4 26 15.06 131.7 27 15.57 8 9 9.8
80 A MUDHARSANA BEGUM 11 4 135 22 12.07 136.7 23 12.31 137 24 12.79 11 11.5 12
81 A AKBAR NISHA 11 4 138 30 15.75 139.6 32 16.42 140.5 33 16.72 10.7 11 11.5
82 A AHMED SHERIN 11 4 143 29 14.18 144.4 31 14.87 145.2 32 15.18 11 11.5 12
83 A ARCHANA 12 3 136 30 16.22 138 32 16.8 139 33 17.08 11 12 12
84 A JABENA 12 4 145 38 18.07 146.4 39 18.2 147 39 18.05 11 12 12.5
85 A ARIFA BEGUM 12 3 y 143 29 14.18 143.5 31 15.05 144 31 14.95 10.7 11.7 12.5
SL.NO GROUP          NAME AGE S.E.STATUS PUB.ATTA HT1 WT1 BMI 1 HT2 WT2 BMI2 HT3 WT3 BMI3 HB1 HB2 HB3
86 A AMMU 12 4 y 147 45 20.82 148 46 21 148.5 47 21.31 11 11.7 12.4
87 A A.SUBASHINI 13 4 y 151 39 17.1 152 40 17.31 152.5 40.5 17.41 11 12 12.4
88 A R.AJISHA 13 4 139 33 17.08 141.2 34 17.05 142 35 17.36 11 12 12.5
89 A THAIYABA 13 4 145 31 14.74 147 31.5 14.58 147.5 32 14.71 9.9 11.4 12.2
90 A A.SHAKIN 12 4 140.5 32 16.21 142.4 33.5 16.52 143.4 34 16.53 11 11.5 12
91 A M.SHAINAZ 13 4 y 147 35 16.2 147.7 36.5 16.73 148 37.5 17.12 9.5 10.5 11
92 A B.SIMRAN 13 4 y 156 42 17.26 157.1 43 17.42 158 44 17.63 11 12 12.5
93 A L.NAAZIABEGUM 14 4 y 156 33 13.56 158.6 35 13.91 159.5 36 14.15 11 11.8 12.5
94 A P.PARVEEN BANU 14 4 y 147 39.5 18.28 149 41 18.47 149.4 42 18.82 11 12 12.5
95 A H.GOWSIA BEGUM 14 4 y 157 59 23.94 158 59.5 23.83 158.5 60 23.88 11 12 12.5
96 A M.MEENA 13 4 y 156.5 37 15.11 158 39.5 15.82 158.5 40 15.92 11 11.6 12.5
97 A R.SHALINI 13 4 y 146.5 51 23.76 147.1 52 24.03 147.4 53 24.39 11 11.6 12.5
98 A SALMA BEGUM 12 4 143 25 12.23 144 25 12.06 144.5 26 12.45 11 12 12.5
99 A E.AMRIN BEGUM 13 4 144 30 14.47 146.2 31 14.5 146.8 32 14.85 11 12 11
100 A K.SHAKILA BANU 13 4 y 150 37 16.44 151.1 38 16.64 151.5 39 16.99 11 11.5 12
101 A F.FOUSIYA 14 3 y 143 52 25.43 144 53 25.56 144.6 54 25.83 10.8 11 11.8
102 A E.DEEPA 13 4 y 144 43 20.74 145 44 20.93 145.5 44.5 21.02 11 11.8 11.9
103 A RAMYA 13 4 133 25 14.13 134 26 14.48 135.5 26.5 14.43 8 9 9.7
104 A NAJMA 13 4 y 143 25 12.23 144 25 12.06 144.5 26 12.45 9 10.4 11.2
105 A FATHIMA 13 4 y 136 30 16.22 137 31 16.52 138.5 32 16.68 7.6 8.2 9.6
106 A A.THASLEEM 12 3 143 52 25.43 144 53 25.56 144.6 54 25.83 10.8
107 A C.UMA 13 4 144 43 20.74 145 44 20.93 145.5 44.5 21.02 11.2
108 A SARASWATHI 13 4 133 25 14.13 134 26 14.48 135.5 26.5 14.43 11.3
109 A PARVEEN BEGUM 14 4 143 25 12.23 144 25 12.06 144.5 26 12.45 9
110 A KUMARI 14 4 136 30 16.22 137 31 16.52 138.5 32 16.68 10.7
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